Abstract : Ventricular septal defects (VSDs) are a common congenital heart disease (approximately 20%). The most common are the perimembranous VSD (around 70%), while completely muscular VSD may occur around 15% of the cases. Supracrystal defects are quite rare accounting for 5% of all VSD. Indications to VSD closure are symptoms of heart failure, signs of left heart chambers overload, and history of endocarditis. The traditional treatment is surgical repair. The surgical approach is considered to be the gold standard, but it is associated with morbidity and mortality, patient discomfort, sternotomy and skin scar. Percutaneous techniques have been developed in order to reduce the impact of such drawback of surgery. Since the first VSD closed by a transcatheter approach by Lock et al. various techniques have been used. Closure of VSD using Ampatzer occluders has been greatly improved and widely reported. VSD inselected patients may be closed percutaneously using an Amplatzer Ductal Occluder II (ADO II) device, as an off-label therapy. It appears that ADO II may be the preferable device for the closure of defects of moderate size (2-5 mm), especially in infants and small children, because of its better profile.